323 related articles for article (PubMed ID: 26339389)
1. Expression of p16 and pRB in invasive breast cancer.
Shin E; Jung WH; Koo JS
Int J Clin Exp Pathol; 2015; 8(7):8209-17. PubMed ID: 26339389
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the Expression of Amine Oxidase Proteins in Breast Cancer.
Sun WY; Choi J; Cha YJ; Koo JS
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29261141
[TBL] [Abstract][Full Text] [Related]
3. Molecular phenotypes of DCIS predict overall and invasive recurrence.
Williams KE; Barnes NLP; Cramer A; Johnson R; Cheema K; Morris J; Howe M; Bundred NJ
Ann Oncol; 2015 May; 26(5):1019-1025. PubMed ID: 25678586
[TBL] [Abstract][Full Text] [Related]
4. Expression of sarcosine metabolism-related proteins in estrogen receptor negative breast cancer according to the androgen receptor and HER-2 status.
Kim MJ; Jung WH; Koo JS
Int J Clin Exp Pathol; 2015; 8(7):7967-77. PubMed ID: 26339363
[TBL] [Abstract][Full Text] [Related]
5. Is biological subtype prognostic of locoregional recurrence risk in women with pT1-2N0 breast cancer treated with mastectomy?
Truong PT; Sadek BT; Lesperance MF; Alexander CS; Shenouda M; Raad RA; Taghian AG
Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):57-64. PubMed ID: 24161421
[TBL] [Abstract][Full Text] [Related]
6. Cell cycle dysregulation influences survival in high risk breast cancer patients.
Königsberg R; Rögelsperger O; Jäger W; Thalhammer T; Klimpfinger M; De Santis M; Hudec M; Dittrich C
Cancer Invest; 2008 Aug; 26(7):734-40. PubMed ID: 18665474
[TBL] [Abstract][Full Text] [Related]
7. Progesterone receptor loss identifies luminal-type local advanced breast cancer with poor survival in patients who fail to achieve a pathological complete response to neoadjuvant chemotherapy.
Chen S; Huang L; Chen CM; Shao ZM
Oncotarget; 2015 Jul; 6(20):18174-82. PubMed ID: 26053183
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
9. Receptor discordance rate and its effects on survival in primary and recurrent breast cancer patients.
Ilgun S; Sarsenov D; Erdogan Z; Ordu C; Celebi F; Nur Pilanci K; Ozturk A; Selamoglu D; Alco G; Aktepe F; Eralp Y; Tuzlali S; Ozmen V
J BUON; 2016; 21(6):1425-1432. PubMed ID: 28039703
[TBL] [Abstract][Full Text] [Related]
10. Yes-associated protein (YAP) is differentially expressed in tumor and stroma according to the molecular subtype of breast cancer.
Kim SK; Jung WH; Koo JS
Int J Clin Exp Pathol; 2014; 7(6):3224-34. PubMed ID: 25031743
[TBL] [Abstract][Full Text] [Related]
11. Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information.
Feeley LP; Mulligan AM; Pinnaduwage D; Bull SB; Andrulis IL
Mod Pathol; 2014 Apr; 27(4):554-61. PubMed ID: 24051696
[TBL] [Abstract][Full Text] [Related]
12. Expression of retinoblastoma protein in breast cancer metastases to sentinel nodes: evaluation of its role as a marker for the presence of metastases in non-sentinel axillary nodes, and comparison to p16INK4a.
Grupka NL; Bloom C; Singh M
Appl Immunohistochem Mol Morphol; 2006 Mar; 14(1):63-70. PubMed ID: 16540733
[TBL] [Abstract][Full Text] [Related]
13. Differential expression of immune-related markers in breast cancer by molecular phenotypes.
Choi J; Kim DH; Jung WH; Koo JS
Breast Cancer Res Treat; 2013 Jan; 137(2):417-29. PubMed ID: 23242618
[TBL] [Abstract][Full Text] [Related]
14. The variation and clinical significance of hormone receptors and Her-2 status from primary to metastatic lesions in breast cancer patients.
Zhu YY; Si W; Ji TF; Guo XQ; Hu Y; Yang JL
Tumour Biol; 2016 Jun; 37(6):7675-84. PubMed ID: 26687919
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of molecular classification of breast invasive ductal carcinoma.
Muñoz M; Fernández-Aceñero MJ; Martín S; Schneider J
Arch Gynecol Obstet; 2009 Jul; 280(1):43-8. PubMed ID: 19082617
[TBL] [Abstract][Full Text] [Related]
16. Promoter hypermethylation of p16, BRCA1 and RASSF1A genes in triple-negative breast cancer patients from Serbia.
Kozomara Z; Supic G; Krivokuca A; Magic Z; Dzodic R; Milovanovic Z; Brankovic-Magic M
J BUON; 2018; 23(3):684-691. PubMed ID: 30003738
[TBL] [Abstract][Full Text] [Related]
17. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
Zhang HM; Zhang BN; Xuan LX; Zhao P
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
[TBL] [Abstract][Full Text] [Related]
18. The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer.
Gabos Z; Thoms J; Ghosh S; Hanson J; Deschênes J; Sabri S; Abdulkarim B
Breast Cancer Res Treat; 2010 Nov; 124(1):187-94. PubMed ID: 20814819
[TBL] [Abstract][Full Text] [Related]
19. The prognostic impact of obesity on molecular subtypes of breast cancer in premenopausal women.
Turkoz FP; Solak M; Petekkaya I; Keskin O; Kertmen N; Sarici F; Arik Z; Babacan T; Ozisik Y; Altundag K
J BUON; 2013; 18(2):335-41. PubMed ID: 23818343
[TBL] [Abstract][Full Text] [Related]
20. Most basal-like breast carcinomas demonstrate the same Rb-/p16+ immunophenotype as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically.
Subhawong AP; Subhawong T; Nassar H; Kouprina N; Begum S; Vang R; Westra WH; Argani P
Am J Surg Pathol; 2009 Feb; 33(2):163-75. PubMed ID: 18936692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
